

January 2015

**ANNUAL DECLARATION OF INTERESTS
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE
BOARD OF DIRECTORS
1 January – 31 December 2014**

GOLD participants disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations each year using the following definitions.

- 1. *Personal Benefits*** refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GOLD member benefits personally. This includes ongoing attendance at advisory board meetings.
- 2. *Shares*** refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GOLD member or family members (spouse/dependent children <18 yrs). The company is to be listed, not the number of shares.
- 3. *Non-Personal Interests*** refers to fees or grants paid to a GOLD Committee member (or the Department/Institution on behalf of a GOLD member) and used for research, education, equipment, salaries, etc.

For each category, items are included in one of two categories: payment or service is valued in excess of \$10,000 (US) but less than \$10,000 and payment or service is valued in excess of \$10,000. The information disclosed by each member of the Board of Directors for the year 2014 is presented in an effort to be as transparent as possible. If the member serves on a Data Safety Monitoring Board, this is so indicated by the designation (DSMB). For more complete background about this process, see “Annual Declaration of Interests: Global Initiative for Chronic Obstructive Lung Disease (GOLD)” on the website at: <<http://www.goldcopd.org>>.

SUMMARY FOR YEAR 2014:

Alvar Agusti, Barcelona, Spain: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, Chiesi, Menarini, Novartis, TEVA. *Personal Benefits* >\$10,000: Almirall, GlaxoSmithKline. *Shares:* none. *Non-Personal Interests* >\$10,000: Almirall, GlaxoSmithKline, Merck Sharp & Dohme.

Jean Bourbeau, Montreal Quebec Canada: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis. *Shares:* none. *Personal Interests* <\$10,000: Merck Sharp & Dohme. *Non-Personal Interests* >\$10,000: Almirall, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis.

Bartolome R. Celli, Boston Massachusetts, USA: *Personal Benefits* <\$10,000: Almirall, Boehringer-Ingelheim (DSMB), GlaxoSmithKline, Novartis (DSMB). *Shares:* none. *Non-Personal Interests:* none.

Rongchang Chen, Guangzhou China: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline. *Shares:* none. *Non-Personal Interests* <\$10,000: AstraZeneca.

Gerard Criner, Philadelphia Pennsylvania, USA: *Personal Benefits* <\$10,000: Holaria. *Shares:* none. *Non-Personal Interests* <\$10,000: Almirall, AstraZeneca, Boehringer-Ingelheim, Celerion, CSA Medical, GlaxoSmithKline, Ikaria, Rosemed. *Non-Personal Interests* >\$10,000: Intermune, J & J, Pneumrx, Pulmonx.

Marc Decramer, Leuven Belgium: *Personal Benefits:* none. *Shares:* none. *Non-Personal Interests:* none.

Peter Frith, Adelaide South Australia, Australia: *Personal Benefits* <\$10,000: GlaxoSmithKline, Healthcare, INC, Novartis, Remedy. *Personal Benefits* >\$10,000: AstraZeneca. *Shares:* none. *Non-Personal Interests:* none.

David Halpin, Devon United Kingdom: *Personal Benefits* <\$10,000: Almirall, AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Napp, Novartis, Pfizer. *Personal Benefits* >\$10,000: Boehringer-Ingelheim. *Shares:* none. *Non-Personal Interests:* none.

Paul Jones, London, UK: *Personal Benefits* <\$10,000: Almirall, Amgen, AstraZeneca, Chiesi, GlaxoSmithKline, Medimmune, Novartis, Pearl, Sandoz. *Personal Benefits* >\$10,000: Almirall. *Shares:* none. *Non-Personal Interests* none.

Maria Victorina López Varela, Montevideo Uruguay: *Personal Benefits* <\$10,000: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis. *Shares:* none. *Non-Personal Interests:* None.

Masaharu Nishimura, Sapporo Japan: *Personal Benefits* <\$10,000: Abbott Japan, GlaxoSmithKline Japan, Nippon Boehringer-Ingelheim, Novartis Japan, Pfizer Japan. *Shares:* none. *Non-Personal Interests* <\$10,000: AstraZeneca, Nippon Boehringer-Ingelheim, Pfizer Japan. *Non-Personal Interests* >\$10,000: Astellas Pharma, GlaxoSmithKline Japan, Novartis Japan.

Claus Vogelmeier, Marburg Germany: *Personal Benefits* <\$10,000: AstraZeneca, Chiesi, GlaxoSmithKline, Grifols, Janssen-Cilag, Mundipharma, Pfizer, Takeda *Personal Benefits* >\$10,000: Boehringer-Ingelheim, Novartis. *Shares:* none. *Non-Personal Interests* >\$10,000: Grifols.

All members confirmed no relation to, or income from, the tobacco industry.